⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101752 | 0.94 | — | — | |
| SCHEMBL6222795 | 0.92 | ALDH1A1 (0.46) | — | |
| SCHEMBL101460 | 0.88 | — | — | |
| SCHEMBL1565996 | 0.77 | DPP4 (0.37) | — | |
| SCHEMBL14728239 | 0.77 | — | — | |
| SCHEMBL4243647 | 0.77 | — | — | |
| SCHEMBL31387737 | 0.75 | CYP1A2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL14716385 | 0.75 | — | — | |
| SCHEMBL16419574 | 0.74 | ALDH1A1 (0.39) | — | |
| SCHEMBL31392705 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986607-B1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-14 | — | — | EP | claimed |
| US-9527867-B2 | Antibacterial biaromatic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-12-27 | — | — | US | claimed |
| US-20160075722-A1 | Antibacterial Biaromatic Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-03-17 | — | — | US | claimed |
| EP-2986607-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-02-24 | — | — | EP | claimed |
| WO-2014170821-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-23 | — | — | WO | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4622712-A1 | SUBSTITUTED MACROCYCLIC AMINE MODULATORS OF OREXIN RECEPTOR 2 | Vertex Pharmaceuticals Incorporated (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| CN-105143216-A | Antibacterial biaromatic derivatives | ACTELION PHARMACEUTICALS LTD | 2015-12-09 | — | — | CN | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-9139577-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20150005278-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| WO-2014170821-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014170821-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-23 | — | — | WO | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |